Niowave, Inc. Tech Stack

Ac-225 radioisotope production via superconducting linear accelerator technology

Pharmaceutical Manufacturing Lansing, Michigan 51–200 employees Founded 2005 Privately Held

Niowave manufactures Actinium-225 using particle-accelerator technology instead of nuclear reactors, targeting oncology therapeutic markets. The tech stack—JMP, Power BI, EtherCAT, Profibus, C++, Python—maps to a manufacturing-heavy operation (10 of 29 open roles) optimizing RF systems, beam optics, and beamline automation. Active pain points around cGMP compliance, process variation, and supply-chain distribution suggest the company is scaling production while hardening regulatory and operational controls.

Tech Stack 12 technologies

Core StackC++ Python Power BI Power Apps Power Automate JMP EtherCAT Profibus Modbus SQL SharePoint Mastercam

What Niowave, Inc. Is Building

◆Challenges

Ensuring compliance with cgmpr requirements
Optimizing system performance
Reporting consistency
Expanding needs of the radioisotopes business
New production facilities
Improving supply chain distribution optimization
Reducing waste
Improving compliance on existing products
Eliminating process variations
Investigating ncmrs & capas

▲Active Projects

Optimization of existing rf systems
Design and implementation of beam optics for superconducting accelerator
Automation of beamline element controls and diagnostics data integration
Radioisotope production operations
New product/process transfers and validations
High-power rf system design for superconducting particle accelerators
Power apps workflow automation
Electron beam line design and build
X-ray conversion target design and operation
Diagnostic system development for particle accelerators

Hiring Activity

Steady30 roles · 10 in 30d

Department

Manufacturing

Engineering

Ops

Logistics

Data

Executive

Regulatory

Support

Seniority

Senior

Mid

Manager

Director

Principal

Notable leadership hires: PMO CMO Director

Company intelligence

Find more companies like Niowave, Inc. by tech stack, pain points and active projects

Get started free

About Niowave, Inc.

Niowave produces Actinium-225, a therapeutic radioisotope for cancer treatment, using superconducting linear accelerators and radiochemistry. Founded in 2005 and based in Lansing, Michigan, the company operates as a private medical-device and radiopharmaceutical manufacturer. The business model avoids the licensing and operational burden of nuclear reactors by using particle accelerators, positioning the production method as simpler and lower-cost. Current operations focus on radioisotope production, process automation, and distribution through existing radiopharmaceutical supply chains. The 51–200-person team is actively hiring across manufacturing, engineering, and operations roles, indicating growth in production capacity and process maturity.

HeadquartersLansing, Michigan

Company Size51–200 employees

Founded2005

Hiring MarketsUnited States

Frequently Asked Questions

What is Niowave's core product?

Niowave manufactures Actinium-225 (Ac-225), a therapeutic radioisotope used in cancer treatment, produced using superconducting linear accelerator technology rather than nuclear reactors.

What tech stack does Niowave use?

JMP, Power BI, Power Apps, SQL, C++, Python, EtherCAT, Profibus, Modbus, SharePoint, Mastercam—primarily manufacturing, control, and automation tools for radioisotope production and beamline management.